Factor II Mutation Screening F2 G20210A
Understanding Factor II Mutation Screening
The Factor II Mutation Screening F2 G20210A is a specialized genetic test that examines the prothrombin gene for specific mutations associated with increased blood clotting risk. Prothrombin, also known as Factor II, is a crucial protein in the blood coagulation cascade. The G20210A mutation represents one of the most common inherited risk factors for thrombophilia, affecting approximately 2-3% of the general population.
This comprehensive screening plays a vital role in identifying individuals with genetic predisposition to venous thromboembolism, deep vein thrombosis, and other clotting disorders. By detecting this specific genetic variation, healthcare providers can implement targeted prevention strategies and personalized treatment approaches for at-risk patients.
What the Test Measures and Detects
The Factor II Mutation Screening specifically targets the G20210A point mutation in the prothrombin gene. This genetic alteration results in:
- Increased prothrombin levels in the bloodstream
- Enhanced thrombin generation and activity
- Elevated risk of inappropriate blood clot formation
- Genetic predisposition to thrombotic events
Using advanced End Point PCR (Polymerase Chain Reaction) combined with RFLP (Restriction Fragment Length Polymorphism) methodology, the test provides highly accurate detection of this specific genetic mutation. The analysis is performed on peripheral blood samples collected in EDTA Vacutainers, ensuring reliable and reproducible results.
Who Should Consider This Test
Clinical Indications and Risk Factors
This genetic screening is particularly important for individuals with:
- Personal history of unexplained blood clots or thrombosis
- Family history of thrombophilia or clotting disorders
- Recurrent pregnancy loss or complications
- Planned major surgical procedures
- Consideration of hormone replacement therapy or oral contraceptives
- Unexplained stroke at a young age
- Multiple family members with venous thromboembolism
- Planning international travel with extended immobility
Symptoms That May Warrant Testing
- Recurrent deep vein thrombosis
- Unexplained pulmonary embolism
- Multiple miscarriages or pregnancy complications
- Family members diagnosed with genetic thrombophilia
- Blood clots occurring without obvious risk factors
Benefits of Factor II Mutation Screening
Undergoing this genetic assessment provides numerous clinical advantages:
- Early Risk Identification: Detect genetic predisposition before thrombotic events occur
- Personalized Prevention: Implement targeted prophylactic measures for high-risk individuals
- Informed Medical Decisions: Guide choices regarding surgery, contraception, and hormone therapy
- Family Planning Guidance: Assess genetic risk for future generations
- Comprehensive Risk Assessment: Combine with other thrombophilia testing for complete evaluation
- Peace of Mind: Provide clarity for individuals with concerning family histories
Understanding Your Test Results
Possible Outcomes and Their Meaning
Negative Result (Normal): No G20210A mutation detected. This indicates you do not carry this specific genetic risk factor for thrombophilia. However, other genetic or acquired risk factors may still be present.
Positive Result (Heterozygous): One copy of the G20210A mutation detected. This increases your risk of developing blood clots, particularly when combined with other risk factors like surgery, immobility, or hormone therapy.
Positive Result (Homozygous): Two copies of the G20210A mutation detected. This represents a significantly higher risk for thrombotic events and requires careful medical management and preventive strategies.
Next Steps After Testing
- Discuss results with your healthcare provider for personalized interpretation
- Consider additional thrombophilia testing if clinically indicated
- Implement appropriate preventive measures based on your genetic risk
- Inform family members about potential inherited risk factors
- Follow up with genetic counseling if desired
Test Details and Pricing
| Test Parameter | Details |
|---|---|
| Test Name | Factor II Mutation Screening F2 G20210A |
| Regular Price | $200 USD |
| Discount Price | $150 USD |
| Turnaround Time | 3-4 Days |
| Sample Type | Peripheral Blood |
| Test Components | EDTA Vacutainer (2ml) |
| Testing Method | End Point PCR + RFLP |
Pre-Test Instructions and Requirements
The Factor II Mutation Screening (F2 – G20210A) requires a Doctor’s prescription for most cases. However, prescription requirements do not apply for:
- Surgery preparation cases
- Pregnancy-related testing
- Individuals planning international travel
No special preparation or fasting is required before sample collection. Our trained phlebotomists will collect the peripheral blood sample using proper techniques to ensure accurate results.
Nationwide Accessibility
We have convenient testing locations across the United States, including major metropolitan areas such as New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose. Our nationwide network ensures accessible genetic testing services with consistent quality standards.
Take Control of Your Genetic Health
Understanding your genetic risk for thrombophilia can be life-changing. The Factor II Mutation Screening provides valuable insights that enable proactive health management and informed medical decisions. With our discounted price of $150 USD (regularly $200 USD) and fast 3-4 day turnaround, there’s never been a better time to assess your genetic risk factors.
Ready to schedule your Factor II Mutation Screening? Contact us today to book your appointment or speak with our genetic counseling team. Call or WhatsApp us at +1(267) 388-9828 to discuss your testing needs and schedule your comprehensive genetic assessment.
Take the first step toward understanding your genetic health and implementing effective prevention strategies. Our expert team is here to guide you through the testing process and help you interpret your results for optimal health outcomes.
